Explore the full record of transactions filed by 임영애, Chief Executive Officer. Officer active across 2 companies, notably 케이엠제약. Cumulatively, 12 disclosures have been recorded. The latest transaction was disclosed on 21 April 2026 (Purchase). Regulator: DART (FSS). All data is free.
Im Young-ae is the Executive Director at KM Pharmaceutical, where he plays a key role in managing operations and strategic development. With extensive experience in the pharmaceutical sector, he oversees projects and ensures process efficiency. His leadership is crucial for the success of KM Pharmaceutical.